Rituximab

Dosage for Rituximab is highly individualized and depends strictly on the condition being treated and the patient's body surface area (BSA).

• Non-Hodgkin’s Lymphoma (NHL): The standard dose is often 375 mg/m² administered as an intravenous infusion. The frequency varies; for example, it may be given once weekly for 4 to 8 doses, or every 3 weeks when combined with chemotherapy.
• Chronic Lymphocytic Leukemia (CLL): The recommended dose is 375 mg/m² for the first cycle, followed by 500 mg/m² for subsequent cycles (Cycles 2 through 6), usually administered every 28 days.
• Rheumatoid Arthritis (RA): Rituximab is administered as two 1000 mg intravenous infusions separated by two weeks. This course is typically repeated every 6 months based on clinical evaluation, but no sooner than every 16 weeks.
• GPA and MPA (Vasculitis): For the induction of remission, the dose is 375 mg/m² once weekly for 4 weeks. For maintenance, doses of 500 mg are typically given at specified intervals.
• Pemphigus Vulgaris: Initial treatment involves two 1000 mg infusions separated by two weeks, followed by maintenance doses of 500 mg at month 12 and every 6 months thereafter.

Rituximab is approved for use in pediatric patients (aged 2 years and older) for specific conditions:

• GPA and MPA: The dose is generally 375 mg/m² once weekly for 4 weeks.
• Pediatric B-cell NHL/B-AL: Dosing is calculated based on BSA and usually administered in combination with chemotherapy protocols.

Safety and effectiveness in pediatric patients for Rheumatoid Arthritis or Pemphigus Vulgaris have not been established. Always consult a pediatric specialist for precise dosing.

Renal Impairment

There are no formal dosage adjustment guidelines provided by the manufacturer for patients with renal impairment. However, because Rituximab is not cleared by the kidneys, significant dose alterations are rarely required. Clinical monitoring remains essential.

Hepatic Impairment

The safety and efficacy of Rituximab have not been studied in patients with hepatic impairment. Since the drug is cleared via proteolysis rather than hepatic metabolism, dose adjustments are generally not expected, but caution is advised.

Elderly Patients

In clinical trials, no overall differences in safety or effectiveness were observed between patients over 65 and younger patients. However, elderly patients may be more susceptible to cardiac or pulmonary complications during the infusion.

Rituximab is not a self-administered medication. It must be given by a healthcare professional in a hospital or clinic.

• Premedication: To reduce the risk of infusion reactions, your doctor will likely give you acetaminophen (Tylenol) and an antihistamine (like diphenhydramine) before each infusion. For RA or GPA/MPA, a glucocorticoid (steroid) is also administered.
• Infusion Speed: The first infusion is always started very slowly. If you tolerate it well, subsequent infusions may be given at a faster rate.
• Observation: You will be monitored closely during the infusion and for at least 15 to 30 minutes afterward for any signs of a reaction.
• Storage: The vials are stored in a refrigerator (2°C to 8°C) and protected from light. They must not be frozen or shaken.

If you miss an appointment for a Rituximab infusion, contact your healthcare provider immediately to reschedule. Because Rituximab works by depleting B-cells over time, maintaining the schedule is critical for therapeutic efficacy. Missing doses in the oncology setting can allow the cancer to progress.

There is limited experience with Rituximab overdose in human clinical trials. Because the drug is administered by professionals, the risk of accidental overdose is low. In the event of an infusion error, the infusion would be stopped immediately, and the patient would be monitored for signs of increased toxicity or severe infusion reactions.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Rituximab will experience some level of side effects, particularly during the first infusion. Common reactions include:

• Infusion-Related Reactions: This is the most frequent side effect. Symptoms include fever, chills, rigors (shaking), and itching. These usually occur within 30 to 120 minutes of starting the first infusion.
• Infections: Because Rituximab depletes B-cells, your immune system's ability to fight infections is lowered. Upper respiratory tract infections, urinary tract infections, and nasopharyngitis (common cold) are frequently reported.
• Asthenia (Weakness): Many patients report a general feeling of tiredness or lack of energy following treatment.
• Gastrointestinal Issues: Nausea, diarrhea, and abdominal pain are common but usually mild to moderate.
• Musculoskeletal Pain: Joint pain (arthralgia) and muscle aches (myalgia) may occur, particularly in patients being treated for Rheumatoid Arthritis.

• Hematologic Changes: Neutropenia (low white blood cells), thrombocytopenia (low platelets), and anemia (low red blood cells) may occur, sometimes with a delayed onset.
• Cardiovascular Effects: Hypotension (low blood pressure) or hypertension (high blood pressure) during the infusion, and peripheral edema (swelling of the hands or feet).
• Skin Reactions: Rash, hives (urticaria), and flushing.
• Neurological Effects: Dizziness, paresthesia (tingling sensation), and anxiety.

• Bowel Perforation: Rare cases of gastrointestinal perforation have been reported, primarily in patients with abdominal lymphoma.
• Cardiac Arrhythmias: Including ventricular fibrillation and supraventricular tachycardia.
• Renal Failure: Acute kidney injury secondary to Tumor Lysis Syndrome (TLS).

> Warning: Stop the infusion (if currently receiving it) and call your doctor immediately if you experience any of the following:

• Severe Infusion Reactions: Shortness of breath, wheezing, swelling of the lips or tongue, chest pain, or a sudden drop in blood pressure. These can be fatal if not treated immediately.
• Progressive Multifocal Leukoencephalopathy (PML): A rare, devastating brain infection. Symptoms include confusion, loss of balance, difficulty walking, vision changes, or weakness on one side of the body.
• Hepatitis B Reactivation: If you have ever had Hepatitis B, Rituximab can cause the virus to become active again, leading to liver failure. Symptoms include yellowing of the skin/eyes (jaundice), dark urine, and right-sided abdominal pain.
• Severe Mucocutaneous Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Look for painful blisters, peeling skin, or sores in the mouth, nose, or eyes.
• Tumor Lysis Syndrome (TLS): Occurs when many cancer cells die quickly and release their contents into the blood. Symptoms include rapid heartbeat, decreased urination, and muscle cramping.

• Hypogammaglobulinemia: Prolonged use of Rituximab can lead to abnormally low levels of antibodies (immunoglobulins) in the blood, which may persist for months or years after the last dose, increasing the long-term risk of infection.
• Delayed Neutropenia: A drop in white blood cell counts that can occur weeks or months after completing therapy.
• Secondary Malignancies: As with many immunosuppressive therapies, there is a theoretical increased risk of developing other types of cancer, though this is not well-quantified for Rituximab alone.

The FDA has issued several Black Box Warnings for Rituximab, the highest level of caution for a medication:

1. 1Fatal Infusion-Related Reactions: 80% of fatal reactions occur during the first infusion. Monitoring is mandatory.
2. 2Severe Mucocutaneous Reactions: Fatal cases of SJS and TEN have been documented.
3. 3Hepatitis B Virus (HBV) Reactivation: Can result in fulminant hepatitis, hepatic failure, and death. Screening is required before starting treatment.
4. 4Progressive Multifocal Leukoencephalopathy (PML): A fatal opportunistic viral infection of the brain.

Report any unusual symptoms to your healthcare provider immediately. Early intervention is key to managing these risks.

Rituximab is a potent biological therapy that significantly alters the immune system. Patients must be fully informed of the risks before beginning treatment. Because Rituximab stays in the body for many months, the risk of side effects and infections continues long after the last infusion.

Rituximab carries four critical FDA Black Box Warnings:

• Infusion-Related Reactions: These reactions are most common with the first infusion. Healthcare facilities must have emergency equipment (oxygen, epinephrine, antihistamines, and corticosteroids) ready.
• Mucocutaneous Reactions: Serious skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have occurred. Some cases were fatal.
• Hepatitis B Reactivation: All patients must be screened for HBV infection before starting Rituximab. Reactivation can lead to liver failure.
• Progressive Multifocal Leukoencephalopathy (PML): This is a rare brain infection caused by the JC virus. It usually results in death or severe disability.

• Allergic Reactions / Anaphylaxis: Beyond the standard infusion reaction, true IgE-mediated anaphylaxis can occur. If a serious allergic reaction occurs, Rituximab must be permanently discontinued.
• Cardiovascular Risks: Patients with a history of heart disease, such as angina or arrhythmias, should be monitored closely. Infusions can cause cardiac stress, and Rituximab should be discontinued if serious arrhythmias occur.
• Renal Toxicity: Tumor Lysis Syndrome (TLS) can lead to acute renal failure. This is most common in oncology patients with a high burden of rapidly dividing cancer cells. Hydration and anti-hyperuricemic medications (like allopurinol) are often used as preventatives.
• Infection Risk: You should not start Rituximab if you have an active, severe infection. This includes chronic infections like Tuberculosis (TB) or HIV, which should be stabilized first.
• Immunizations: You should not receive "live" vaccines (such as the MMR or chickenpox vaccine) while taking Rituximab. The vaccine may not work, or it could cause the disease it was intended to prevent.

Your healthcare provider will perform regular tests to ensure the drug is working safely:

• Complete Blood Counts (CBC): To monitor for low white blood cells, red blood cells, and platelets.
• Liver Function Tests (LFTs): To check for signs of liver stress or Hepatitis B reactivation.
• Renal Function: Monitoring serum creatinine and electrolytes, especially in oncology patients.
• B-cell Levels: Sometimes measured to see how well the drug is depleting the target cells.
• Cardiac Monitoring: For patients with pre-existing heart conditions during the infusion.

Rituximab itself is unlikely to affect your ability to drive. However, the premedications (like diphenhydramine/Benadryl) often cause significant drowsiness. It is recommended that you have someone drive you to and from your infusion appointments.

There is no direct contraindication between Rituximab and alcohol. However, alcohol can exacerbate certain side effects like dizziness and nausea. Additionally, for patients with underlying liver issues or those taking methotrexate (common in RA), alcohol should be strictly limited or avoided.

Rituximab does not have a "withdrawal syndrome," but discontinuing it in the middle of a treatment course for cancer or vasculitis can lead to a rapid relapse of the disease. If the drug must be stopped due to toxicity, your doctor will transition you to an alternative therapy.

> Important: Discuss all your medical conditions, especially heart, liver, or lung disease, with your healthcare provider before starting Rituximab.

While there are few absolute contraindications for drug combinations with Rituximab, the following should be avoided:

• Live Viral Vaccines: (e.g., Yellow Fever, Live Flu Mist, Zoster). The clinical consequence is a risk of disseminated viral infection due to the patient's compromised immune state. Additionally, the vaccine will likely be ineffective because the B-cells required to create antibodies have been depleted.

• Cisplatin: When used in oncology, the combination of Rituximab and cisplatin may increase the risk of renal toxicity. Kidney function must be monitored rigorously.
• Biological DMARDs: (e.g., Adalimumab, Etanercept, Infliximab). Using Rituximab concurrently with other biological therapies for Rheumatoid Arthritis is generally not recommended due to an excessively high risk of serious infections.
• Other Immunosuppressants: (e.g., Cyclosporine, Azathioprine). These can have an additive effect on the immune system, increasing the risk of opportunistic infections.

• Antihypertensives: Because Rituximab infusions can cause transient hypotension (low blood pressure), your doctor may advise you to withhold your blood pressure medication for 12 to 24 hours before the infusion to prevent severe drops in pressure.
• Methotrexate: While commonly used together in RA, the combination requires careful monitoring of blood counts as both can cause bone marrow suppression.

• Grapefruit: Unlike many drugs, Rituximab is not metabolized by the CYP3A4 enzyme, so grapefruit does not significantly affect its levels.
• Dairy and High-Fat Meals: There are no known interactions with food, as the drug bypasses the digestive system.
• Caffeine: May worsen the heart rate increases sometimes seen during infusion reactions.

• Echinacea: Often used to stimulate the immune system, Echinacea may theoretically oppose the immunosuppressive effects of Rituximab. Its use is generally discouraged.
• St. John's Wort: While it affects many drugs via CYP enzymes, it has no known direct interaction with Rituximab, though it may complicate the management of other medications the patient is taking.
• Turmeric/Curcumin: High doses may have anticoagulant effects, which could be a concern if Rituximab causes low platelet counts.

• Diagnostic Serology: Because Rituximab depletes B-cells and lowers antibody levels, blood tests that look for antibodies (like those for Hepatitis, Lyme disease, or even COVID-19) may yield false-negative results.
• Human Anti-Chimeric Antibody (HACA) Test: Patients may develop antibodies against Rituximab itself, which can interfere with the drug's efficacy and increase reaction risks.

For each major interaction, the mechanism is usually pharmacodynamic (how the drugs affect the body) rather than pharmacokinetic (how the body affects the drug). The clinical consequence is usually an increased risk of infection or reduced vaccine response. Management strategies involve timing doses carefully and performing frequent blood work.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.

Rituximab must NEVER be used in the following circumstances:

• Severe Hypersensitivity: Patients who have had a known anaphylactic or severe infusion reaction to Rituximab or any of its components (including murine/mouse proteins) must not receive the drug again.
• Active, Severe Infections: If a patient is suffering from a life-threatening infection (e.g., sepsis, active pneumonia), Rituximab must be withheld until the infection is fully resolved, as the drug will prevent the immune system from mounting a proper defense.

Conditions requiring careful risk-benefit analysis include:

• History of Recurrent Infections: Patients prone to chronic infections may face a higher risk of serious complications.
• Hepatitis B Carriers: Patients with positive HBV serology require prophylactic antiviral therapy and extreme caution.
• Pre-existing Cardiac Disease: Patients with a history of heart failure or arrhythmias are at higher risk for infusion-related cardiac stress.
• Low Baseline Neutrophil Count: If white blood cell counts are already very low (ANC < 1000 cells/mm³), the risk of life-threatening infection is significantly higher.
• Pregnancy: Rituximab should only be used if the potential benefit to the mother outweighs the potential risk to the fetus.

Rituximab is a chimeric antibody containing human and mouse protein sequences. Patients with a known allergy to other monoclonal antibodies or to mouse-derived products may be at a higher risk for cross-sensitivity and should be evaluated by an allergist before treatment.

> Important: Your healthcare provider will evaluate your complete medical history, including your immunization status and infection history, before prescribing Rituximab.

Rituximab is classified as a drug that can cause fetal harm. It is an IgG1 monoclonal antibody, and it is known to cross the placental barrier, particularly during the second and third trimesters.

• Fetal Risks: B-cell depletion has been reported in infants born to mothers exposed to Rituximab during pregnancy. While these B-cell levels usually normalize within 6 months of birth, the infant may be at an increased risk of infection during that time.
• Contraception: Women of childbearing potential should use effective contraception during treatment and for 12 months after the last dose of Rituximab due to its long half-life.

Limited data suggest that Rituximab is excreted in human breast milk in very small amounts. Because Rituximab is a large protein molecule, much of what is ingested by the infant would likely be degraded in the infant's gastrointestinal tract. However, the effects on the nursing infant are not fully known. Most clinicians recommend weighing the benefits of breastfeeding against the potential risks of B-cell depletion in the infant.

Rituximab is approved for pediatric patients (2 years and older) for GPA, MPA, and certain B-cell lymphomas.

• Growth Effects: There is no evidence that Rituximab affects long-term growth in children.
• Vaccinations: Pediatric patients should be brought up to date with all immunizations before starting therapy. Live vaccines are strictly prohibited during and for several months after therapy.

Clinical studies did not identify significant differences in the efficacy of Rituximab in elderly patients (65+). However, older patients are more likely to have co-morbidities (like heart or lung disease) that make infusion reactions more dangerous. There is also a slightly higher rate of serious infections in the elderly population compared to younger patients.

No dosage adjustment is required for patients with renal impairment. Rituximab is not eliminated by the kidneys. However, patients with pre-existing renal issues should be monitored for Tumor Lysis Syndrome, which can further damage the kidneys.

No studies have been conducted in patients with hepatic impairment. While the liver is not the primary site of metabolism, these patients should be monitored closely for general safety, especially if they are Hepatitis B carriers.

> Important: Special populations require individualized medical assessment and often more frequent lab monitoring.

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody. The 'chimeric' nature means it is composed of the variable regions of a mouse antibody (which bind to CD20) and the constant regions of a human IgG1 antibody (which interact with the human immune system).

The drug targets the CD20 antigen, a hydrophobic transmembrane protein. CD20 is involved in B-cell activation and proliferation. Upon binding, Rituximab initiates B-cell lysis through:

• CDC: Activation of the classical complement pathway.
• ADCC: Recruitment of effector cells like NK cells.
• Direct Apoptosis: Induction of intracellular signaling pathways that lead to cell death.

• B-cell Depletion: Following the first infusion, B-cell counts in the peripheral blood typically fall to undetectable levels within 2 to 3 weeks.
• Recovery: B-cell recovery usually begins 6 months after treatment ends, with levels returning to normal by 12 months, though this can take much longer in some patients.
• Duration of Effect: In RA, the clinical benefits of a single course can last 6 to 12 months.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV) |

| Protein Binding | Not applicable (it is a protein) |

| Half-life | 18–32 days (Indication dependent) |

| Tmax | Immediate (end of infusion) |

| Metabolism | Proteolysis (non-CYP) |

| Excretion | Cellular uptake and degradation |

• Molecular Formula: C6412H9908N1694O1987S44
• Molecular Weight: Approximately 145,000 Daltons
• Solubility: Soluble in water-based buffers (saline)
• Structure: Consists of two heavy chains of 451 amino acids and two light chains of 213 amino acids.

Rituximab is the prototypical CD20-directed cytolytic antibody. It paved the way for newer generations of CD20 antibodies, such as Ofatumumab (fully human) and Obinutuzumab (glycoengineered). In the context of autoimmune disease, it is considered a Biologic Disease-Modifying Antirheumatic Drug (bDMARD).